With a view to the very different hygiene requirements in individual pharmaceutical processes, GEA engineers have developed a fully comprehensive portfolio of plug-and-produce pharmaceutical separators
On display at ACHEMA 2022 in Frankfurt, Germany (Hall 4.0 G66), the aseptic and pure separator lines are used in all pharmaceutical and biotechnological downstream processes and meet customer-specific as well as process-required demands.
GEA sees the uncompromising hygienic design reliability and the possibility of maximum yield in the respective processes as the decisive plus points of aseptic and pure.
The pharmaceutical separator lines "aseptic" and "pure" are developed to the highest GEA standards at the German GEA Westfalia Separator plant in Oelde, where they are built and tested.
All features for pharmaceutical cleanliness requirements such as an automatic CIP (clean-in-place), SIP (sterilise-in-place), easy validation and a high-end qualification package are included.
In addition, the pharmaceutical separators support GEA customers in their quality standard reviews with the help of the cGMP validation process (current Good Manufacturing Practice).
The aseptic line includes SIP processing and stands for the highest hygienic pharmaceutical requirements. It offers customers with highly hygienic processes gentle processing of, for example, human and veterinary vaccines, monoclonal antibodies (mAb), E. coli, insulin, starter cultures and probiotic products.
The pure line gives highest variability and is perfectly tailored to the diverse process requirements of the biopharma industry. It is recommended for customers with applications with varying hygienic requirements, such as for food supplements, therapeutic proteins, pharmaceutical extractions, and in the recovery of extracellular and intracellular enzymes.
Here, the separator line pure offers the highest variability in the selection of required hygienic components.
The GEA flexChange 3-in-1 bowl concept of the new separator series aseptic and pure ensures high flexibility, which means a plus in competitiveness especially for contract manufacturing organisations (CMO) and operators of pilot plant.
The principle: the customer selects the bowl variant ideally suited to his products with solid content from 5 vol% to 35 vol% or higher, depending on product. This results in maximum yield with every product change. One GEA Pharma Skid with flexChange concept thus replaces three plants.